Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Vigilare Wealth Management


Share on StockTwits

Vigilare Wealth Management decreased its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 25.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,525 shares of the biopharmaceutical company’s stock after selling 4,675 shares during the period. Vigilare Wealth Management’s holdings in Ocular Therapeutix were worth $280,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. grew its position in Ocular Therapeutix by 12.9% during the 3rd quarter. BlackRock Inc. now owns 4,084,064 shares of the biopharmaceutical company’s stock worth $31,080,000 after purchasing an additional 466,439 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Ocular Therapeutix by 43.2% during the second quarter. Vanguard Group Inc. now owns 3,007,159 shares of the biopharmaceutical company’s stock valued at $25,050,000 after acquiring an additional 907,320 shares during the last quarter. Deltec Asset Management LLC raised its stake in shares of Ocular Therapeutix by 6.1% during the third quarter. Deltec Asset Management LLC now owns 2,472,067 shares of the biopharmaceutical company’s stock valued at $18,812,000 after acquiring an additional 141,800 shares during the last quarter. State Street Corp raised its stake in shares of Ocular Therapeutix by 26.9% during the third quarter. State Street Corp now owns 1,149,467 shares of the biopharmaceutical company’s stock valued at $8,747,000 after acquiring an additional 243,485 shares during the last quarter. Finally, Morgan Stanley raised its stake in shares of Ocular Therapeutix by 34.9% during the third quarter. Morgan Stanley now owns 264,627 shares of the biopharmaceutical company’s stock valued at $2,014,000 after acquiring an additional 68,514 shares during the last quarter. 53.24% of the stock is owned by institutional investors and hedge funds.

OCUL has been the subject of several recent analyst reports. Piper Sandler upped their price objective on shares of Ocular Therapeutix from $16.00 to $28.00 in a research note on Monday, December 21st. Raymond James boosted their price target on shares of Ocular Therapeutix from $15.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 13th. Berenberg Bank assumed coverage on shares of Ocular Therapeutix in a research report on Thursday, December 17th. They set a “buy” rating and a $27.00 price target on the stock. HC Wainwright cut shares of Ocular Therapeutix from a “buy” rating to a “neutral” rating in a research report on Monday, December 28th. Finally, JMP Securities boosted their price target on shares of Ocular Therapeutix from $20.00 to $30.00 in a research report on Wednesday, December 30th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Ocular Therapeutix presently has a consensus rating of “Buy” and an average price target of $21.86.

OCUL stock traded up $0.61 on Thursday, reaching $21.93. 13,110 shares of the company traded hands, compared to its average volume of 800,453. The firm has a fifty day simple moving average of $20.48 and a 200-day simple moving average of $12.17. The company has a market cap of $1.66 billion, a P/E ratio of -11.91 and a beta of 2.27. Ocular Therapeutix, Inc. has a one year low of $3.78 and a one year high of $24.30. The company has a debt-to-equity ratio of 8.86, a current ratio of 3.58 and a quick ratio of 3.53.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.02. Ocular Therapeutix had a negative return on equity of 14,065.71% and a negative net margin of 780.19%. The business had revenue of $5.88 million for the quarter, compared to the consensus estimate of $5.85 million. On average, sell-side analysts forecast that Ocular Therapeutix, Inc. will post -0.8 EPS for the current year.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Read More: What is a Fiduciary?

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL).

Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.